# Exploiting human fucosyltransferase 8 allostery with a covalent inhibitor for core fucosylation suppression

## TL;DR

Researchers found a new way to inhibit the FUT8 enzyme, which is involved in cancer progression, by developing a covalent inhibitor that targets an allosteric site.

## Contribution

The discovery of a previously unrecognized allosteric site on FUT8 and the development of a selective covalent inhibitor, CAIF.

## Key findings

- CAIF covalently targets lysine K216 in the allosteric site of FUT8, inhibiting core fucosylation.
- CAIF shows minimal cytotoxicity and significantly suppresses cancer cell invasion in cellular assays.
- Crystallographic studies reveal small molecules bind to an allosteric pocket, altering FUT8 conformation.

## Abstract

Core fucosylation, catalyzed by fucosyltransferase 8 (FUT8), plays critical roles in cancer progression, immune evasion, and drug resistance, making it a compelling therapeutic target. However, development of selective FUT8 inhibitors has been hindered by shared substrate specificity of fucosyltransferases. Here, we report the discovery of a previously unrecognized allosteric site on FUT8 and the development of a low-toxicity covalent inhibitor, CAIF (stearic acid-N-hydroxysuccinimide ester-dimethylimidazolium bromide), through structure-based drug design. High-throughput screening and crystallographic studies reveal that small molecules such as NH125 bind to a channel-like allosteric pocket, inducing conformational changes that disrupt FUT8 activity. Leveraging these insights, we design CAIF to covalently target lysine K216 within the allosteric site. CAIF exhibits minimal cytotoxicity and significantly inhibits core fucosylation and cancer cell invasion in cellular assays. This work establishes CAIF as a lead compound for further optimization and development, offering a framework for targeting glycosyltransferases through allosteric and covalent inhibition strategies.

This study discovers an allosteric site on the enzyme FUT8 and develops a selective covalent inhibitor, CAIF. CAIF blocks core fucosylation and suppresses cancer cell invasion in vitro, revealing a promising strategy against FUT8-driven diseases.